NAMS

SEC source: 0000950170-25-081072 · ownership.xml · derivative · entry 2

LANGE LOUIS G · CIK 0001238401 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 68 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share.

F4 · price: The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date under the BCA (the "Closing Date"). The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date.

F3 · derivative.exercise_date: 3,102 RSUs vested upon grant, 69 RSUs vested on April 1, 2025,69 RSUs vested on May 1, 2025 and 68 RSUs vested on June 1, 2025.

F3 · derivative.expiration_date: 3,102 RSUs vested upon grant, 69 RSUs vested on April 1, 2025,69 RSUs vested on May 1, 2025 and 68 RSUs vested on June 1, 2025.

SEC source: 0000950170-25-081072 · ownership.xml · nonDerivative · entry 1

LANGE LOUIS G · CIK 0001238401 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 28,186

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: The shares are held directly by LGLange III Trust DTD10 (the "Trust") for the benefit of the Reporting Person.

SEC source: 0000950170-25-074463 · ownership.xml · derivative · entry 3

Kling Douglas F · CIK 0001699022 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 450,930

Underlying: Ordinary Shares · 100,000 shares

Expires 2032-11-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 22, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date.

SEC source: 0000950170-25-074463 · ownership.xml · nonDerivative · entry 2

Kling Douglas F · CIK 0001699022 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,000

F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · price: These shares were sold in multiple transactions at prices ranging from $18.38 per share to $18.89 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

SEC source: 0000950170-25-074463 · ownership.xml · nonDerivative · entry 1

Kling Douglas F · CIK 0001699022 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 144,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-25-062897 · ownership.xml · derivative · entry 1

Audet Juliette Berangere · CIK 0002000393 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Ordinary Shares · 30,000 shares

Expires 2035-05-01

F1 · derivative.exercise_date: 25% of the shares underlying the option will vest on May 1, 2026, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through such date.

SEC source: 0000950170-25-062894 · ownership.xml · derivative · entry 2

LANGE LOUIS G · CIK 0001238401 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68

Underlying: Ordinary Shares · 69 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share.

F4 · price: The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date under the BCA (the "Closing Date"). The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date.

F3 · derivative.exercise_date: 3,102 RSUs vested upon grant, 69 RSUs vested on April 1, 2025 and 69 RSUs vested on May 1, 2025. The 68 remaining RSUs will vest on June 1, 2025, subject to the Reporting Person's continued service with the issuer as of each of the vesting date.

F3 · derivative.expiration_date: 3,102 RSUs vested upon grant, 69 RSUs vested on April 1, 2025 and 69 RSUs vested on May 1, 2025. The 68 remaining RSUs will vest on June 1, 2025, subject to the Reporting Person's continued service with the issuer as of each of the vesting date.

SEC source: 0000950170-25-062894 · ownership.xml · nonDerivative · entry 1

LANGE LOUIS G · CIK 0001238401 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 28,118

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: The shares are held directly by LGLange III Trust DTD10 (the "Trust") for the benefit of the Reporting Person.

SEC source: 0000950170-25-055612 · ownership.xml · derivative · entry 4

Kling Douglas F · CIK 0001699022 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 550,930

Underlying: Ordinary Shares · 100,000 shares

Expires 2032-11-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 22, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date.

SEC source: 0000950170-25-055612 · ownership.xml · nonDerivative · entry 3

Kling Douglas F · CIK 0001699022 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,000

F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F3 · price: These shares were sold in multiple transactions at prices ranging from $16.70 per share to $16.88 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

SEC source: 0000950170-25-055612 · ownership.xml · nonDerivative · entry 2

Kling Douglas F · CIK 0001699022 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,910

F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · price: These shares were sold in multiple transactions at prices ranging from $15.70 per share to $16.65 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

SEC source: 0000950170-25-055612 · ownership.xml · nonDerivative · entry 1

Kling Douglas F · CIK 0001699022 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 144,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-25-055603 · ownership.xml · derivative · entry 2

Gulfo Adele M. · CIK 0001647102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,700

Underlying: Ordinary Shares · 50,700 shares

Expires 2035-04-15

F3 · derivative.exercise_date: 33% of the shares underlying the option will vest on April 15, 2026, the one-year anniversay of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for two years, subject to the Reporting Person's continued service through each such date.

SEC source: 0000950170-25-055603 · ownership.xml · nonDerivative · entry 1

Gulfo Adele M. · CIK 0001647102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,860

F1 · shares: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date.

F2 · price: Each RSU was granted on April 15, 2025 for no consideration.

SEC source: 0000950170-25-056395 · ownership.xml · derivative · entry 2

LANGE LOUIS G · CIK 0001238401 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137

Underlying: Ordinary Shares · 69 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share.

F4 · price: The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date.

F3 · derivative.exercise_date: 3,102 RSUs vested upon grant and 69 RSUs vested on April 1, 2025. The remaining RSUs will vest as follows, subject to the Reporting Person's continued service with the issuer as of each of the applicable vesting dates: 69 of the remaining RSUs will vest on May 1, 2025 and 68 of the remaining RSUs will vest on June 1, 2025.

F3 · derivative.expiration_date: 3,102 RSUs vested upon grant and 69 RSUs vested on April 1, 2025. The remaining RSUs will vest as follows, subject to the Reporting Person's continued service with the issuer as of each of the applicable vesting dates: 69 of the remaining RSUs will vest on May 1, 2025 and 68 of the remaining RSUs will vest on June 1, 2025.

SEC source: 0000950170-25-056395 · ownership.xml · nonDerivative · entry 1

LANGE LOUIS G · CIK 0001238401 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 28,049

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: The shares are held directly by LGLange III Trust DTD10 (the "Trust") for the benefit of the Reporting Person. The Reporting Person inadvertently reported the ownership of 3,102 ordinary shares issued upon vesting of restricted stock units ("RSUs") on March 28, 2025 to his direct holdings. Such ordinary shares are held by the Trust, and this Form 4 reflects the Reporting Person's correct direct and indirect holdings.

SEC source: 0000950170-25-046962 · ownership.xml · derivative · entry 3

Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 8,269 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share.

F3 · price: The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date.

F2 · derivative.exercise_date: Upon grant, all of the RSUs were fully-vested.

F2 · derivative.expiration_date: Upon grant, all of the RSUs were fully-vested.

SEC source: 0000950170-25-046962 · ownership.xml · derivative · entry 2

Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,269

Underlying: Ordinary Shares · 8,269 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share.

F3 · price: The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date.

F2 · derivative.exercise_date: Upon grant, all of the RSUs were fully-vested.

F2 · derivative.expiration_date: Upon grant, all of the RSUs were fully-vested.

SEC source: 0000950170-25-046962 · ownership.xml · nonDerivative · entry 1

Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,269

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-25-046947 · ownership.xml · derivative · entry 4

Kastelein Johannes Jacob Pieter · CIK 0002000389 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 45,481 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share.

F5 · price: The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the BCA. The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date.

F4 · derivative.exercise_date: Upon grant, all of the RSUs were fully-vested.

F4 · derivative.expiration_date: Upon grant, all of the RSUs were fully-vested.

SEC source: 0000950170-25-046947 · ownership.xml · derivative · entry 3

Kastelein Johannes Jacob Pieter · CIK 0002000389 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,481

Underlying: Ordinary Shares · 45,481 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share.

F5 · price: The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the BCA. The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date.

F4 · derivative.exercise_date: Upon grant, all of the RSUs were fully-vested.

F4 · derivative.expiration_date: Upon grant, all of the RSUs were fully-vested.

SEC source: 0000950170-25-046947 · ownership.xml · nonDerivative · entry 2

Kastelein Johannes Jacob Pieter · CIK 0002000389 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,481

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-25-046947 · ownership.xml · nonDerivative · entry 1

Kastelein Johannes Jacob Pieter · CIK 0002000389 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 169,302

F1 · shares: Reflects ordinary shares issued to Futurum B.V. ("Futurum") for the benefit of the Reporting Person on March 26, 2025 as earnout shares pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain shareholders would receive additional ordinary shares of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of November 22, 2022, the date of closing under the BCA (the "Closing Date"). Futurum's right to receive the earnout shares became fixed and irrevocable on the Closing Date.

F2 · ownership.nature: The ordinary shares are held by Futurum for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the ordinary shares held by Futurum.

SEC source: 0001415889-25-009198 · form4-03282025_090345.xml · nonDerivative · entry 1

Topper James N · CIK 0001341382 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Frazier Life Sciences X, L.P.

Disclosed balance after: 3,013,569

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.37 to $22.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.

F2 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0000950170-25-046958 · ownership.xml · derivative · entry 3

LANGE LOUIS G · CIK 0001238401 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 206

Underlying: Ordinary Shares · 3,102 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share.

F3 · price: The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date.

F2 · derivative.exercise_date: Upon grant, 3,102 RSUs were fully-vested. The remaining RSUs will vest as follows, subject to the Reporting Person's continued service with the Company as of each of the applicable vesting dates: 69 of the remaining RSUs will vest on April 1, 2025; 69 of the remaining RSUs will vest on May 1, 2025; and 68 of the remaining RSUs will vest on June 1, 2025.

F2 · derivative.expiration_date: Upon grant, 3,102 RSUs were fully-vested. The remaining RSUs will vest as follows, subject to the Reporting Person's continued service with the Company as of each of the applicable vesting dates: 69 of the remaining RSUs will vest on April 1, 2025; 69 of the remaining RSUs will vest on May 1, 2025; and 68 of the remaining RSUs will vest on June 1, 2025.

SEC source: 0000950170-25-046958 · ownership.xml · derivative · entry 2

LANGE LOUIS G · CIK 0001238401 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,308

Underlying: Ordinary Shares · 3,308 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share.

F3 · price: The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date.

F2 · derivative.exercise_date: Upon grant, 3,102 RSUs were fully-vested. The remaining RSUs will vest as follows, subject to the Reporting Person's continued service with the Company as of each of the applicable vesting dates: 69 of the remaining RSUs will vest on April 1, 2025; 69 of the remaining RSUs will vest on May 1, 2025; and 68 of the remaining RSUs will vest on June 1, 2025.

F2 · derivative.expiration_date: Upon grant, 3,102 RSUs were fully-vested. The remaining RSUs will vest as follows, subject to the Reporting Person's continued service with the Company as of each of the applicable vesting dates: 69 of the remaining RSUs will vest on April 1, 2025; 69 of the remaining RSUs will vest on May 1, 2025; and 68 of the remaining RSUs will vest on June 1, 2025.

SEC source: 0000950170-25-046958 · ownership.xml · nonDerivative · entry 1

LANGE LOUIS G · CIK 0001238401 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,062

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-25-046934 · ownership.xml · derivative · entry 5

Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 38,394 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share.

F6 · price: The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the BCA. The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date.

F5 · derivative.exercise_date: Upon grant, all of the RSUs were fully-vested.

F5 · derivative.expiration_date: Upon grant, all of the RSUs were fully-vested.

SEC source: 0000950170-25-046934 · ownership.xml · derivative · entry 4

Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,394

Underlying: Ordinary Shares · 38,394 shares

Expires not disclosed

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share.

F6 · price: The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the BCA. The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date.

F5 · derivative.exercise_date: Upon grant, all of the RSUs were fully-vested.

F5 · derivative.expiration_date: Upon grant, all of the RSUs were fully-vested.

SEC source: 0000950170-25-046934 · ownership.xml · nonDerivative · entry 3

Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 390,441

F2 · shares: Ordinary shares sold to satisfy tax withholding obligation arising upon the vesting of restricted stock units ("RSUs").

F3 · price: These shares were sold in multiple transactions at a price ranging from $22.88 to $23.22 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities Exchange Comission, upon request, full information regarding the number of shares sold in each transaction.

SEC source: 0000950170-25-046934 · ownership.xml · nonDerivative · entry 2

Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 402,699

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-25-046934 · ownership.xml · nonDerivative · entry 1

Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 364,305

F1 · shares: Reflects ordinary shares issued to the Reporting Person on March 26, 2025 as earnout shares pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain shareholders would receive additional ordinary shares of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of November 22, 2022, the date of closing under the BCA (the "Closing Date"). The Reporting Person's right to receive the earnout shares became fixed and irrevocable on the Closing Date.

SEC source: 0000950170-25-046943 · ownership.xml · derivative · entry 4

Kling Douglas F · CIK 0001699022 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 16,539 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share.

F4 · price: The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date.

F3 · derivative.exercise_date: Upon grant, all of the RSUs were fully-vested.

F3 · derivative.expiration_date: Upon grant, all of the RSUs were fully-vested.

SEC source: 0000950170-25-046943 · ownership.xml · derivative · entry 3

Kling Douglas F · CIK 0001699022 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,539

Underlying: Ordinary Shares · 16,539 shares

Expires not disclosed

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share.

F4 · price: The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date.

F3 · derivative.exercise_date: Upon grant, all of the RSUs were fully-vested.

F3 · derivative.expiration_date: Upon grant, all of the RSUs were fully-vested.

SEC source: 0000950170-25-046943 · ownership.xml · nonDerivative · entry 2

Kling Douglas F · CIK 0001699022 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,000

F1 · price: These shares were sold in multiple transactions at a price ranging from $22.75 to $23.20 per share. A portion of the ordinary shares were sold to satisfy tax withholding obligations arising upon the vesting of the restricted stock units ("RSUs"). The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities Exchange Comission, upon request, full information regarding the number of shares sold in each transaction.

SEC source: 0000950170-25-046943 · ownership.xml · nonDerivative · entry 1

Kling Douglas F · CIK 0001699022 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,539

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-25-045283 · ownership.xml · derivative · entry 2

Kastelein Johannes Jacob Pieter · CIK 0002000389 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 820,229

Underlying: Ordinary Shares · 150,000 shares

Expires 2031-07-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price of the option is 1.16392 Euros.

F3 · derivative.exercise_date: The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 292,214 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.

F4 · ownership.nature: The option was granted to and is held by Futurum through NAP PoolCo B.V. ("PoolCo") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum. Upon exercise of the option, the Ordinary Shares were issued to Futurum directly, pursuant to a written agreement among Futurum, PoolCo and the issuer.

SEC source: 0000950170-25-045283 · ownership.xml · nonDerivative · entry 1

Kastelein Johannes Jacob Pieter · CIK 0002000389 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 150,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price of the option is 1.16392 Euros.

F2 · ownership.nature: The Ordinary Shares are held by Futurum B.V. ("Futurum") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the Ordinary Shares held by Futurum.

SEC source: 0000950170-25-042176 · ownership.xml · derivative · entry 5

Kling Douglas F · CIK 0001699022 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 650,930

Underlying: Ordinary Shares · 11,888 shares

Expires 2032-11-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 22, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date.

SEC source: 0000950170-25-042176 · ownership.xml · derivative · entry 4

Kling Douglas F · CIK 0001699022 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,251

Underlying: Ordinary Shares · 88,112 shares

Expires 2031-07-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The exercise price of the option is 1.16392 euros.

F4 · derivative.exercise_date: The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021, which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 121,754 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on March 31, 2022, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.

SEC source: 0000950170-25-042176 · ownership.xml · nonDerivative · entry 3

Kling Douglas F · CIK 0001699022 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,000

F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F3 · price: These shares were sold in multiple transactions at prices ranging from $23.16 per share to $23.66 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

SEC source: 0000950170-25-042176 · ownership.xml · nonDerivative · entry 2

Kling Douglas F · CIK 0001699022 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 144,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-25-042176 · ownership.xml · nonDerivative · entry 1

Kling Douglas F · CIK 0001699022 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 132,112

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The exercise price of the option is 1.16392 euros.

SEC source: 0000950170-25-033927 · ownership.xml · derivative · entry 3

Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,073

Underlying: Ordinary Shares · 150,000 shares

Expires 2031-07-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price of the option is EUR 1.16392.

F3 · derivative.exercise_date: The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 60,879 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.

F2 · ownership.direct: The securities were previously held indirectly by the Reporting Person through LouFre Management B.V. ("LouFre") for the benefit of the Reporting Person. The Reporting Person had the sole pecuniary interest in the securities.

SEC source: 0000950170-25-033927 · ownership.xml · nonDerivative · entry 2

Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

SEC source: 0000950170-25-033927 · ownership.xml · nonDerivative · entry 1

Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 165,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price of the option is EUR 1.16392.

F2 · ownership.direct: The securities were previously held indirectly by the Reporting Person through LouFre Management B.V. ("LouFre") for the benefit of the Reporting Person. The Reporting Person had the sole pecuniary interest in the securities.

SEC source: 0001415889-25-007263 · form4-03062025_100302.xml · nonDerivative · entry 1

Topper James N · CIK 0001341382 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Frazier Life Sciences X, L.P.

Disclosed balance after: 3,012,434

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.545 to $21.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.

F2 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0000950170-25-024322 · ownership.xml · derivative · entry 6

Kling Douglas F · CIK 0001699022 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 126,145

Underlying: Ordinary Shares · 9,218 shares

Expires 2031-07-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F5 · derivative.exercise_date: The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021, which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 121,754 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on March 31, 2022, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.

SEC source: 0000950170-25-024322 · ownership.xml · nonDerivative · entry 4

Kling Douglas F · CIK 0001699022 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,000

F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F4 · price: These shares were sold in multiple transactions at prices ranging from $19.23 per share to $20.18 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

SEC source: 0000950170-25-024322 · ownership.xml · nonDerivative · entry 3

Kling Douglas F · CIK 0001699022 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 53,218

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The exercise price of the option is 1.16392 euros.